Search results
Showing 46 to 60 of 84 results for colitis
BD MAX Enteric Bacterial Panel for identifying pathogens in contagious gastroenteritis (MIB32)
NICE has developed a medtech innovation briefing (MIB) on BD MAX Enteric Bacterial Panel for identifying pathogens in contagious gastroenteritis .
Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827]
Awaiting development Reference number: GID-TA10717 Expected publication date: TBC
Evidence-based recommendations on Barnett Continent Intestinal Reservoir (modified continent ileostomy) to restore continence after colon and rectum removal in adults. This involves using the ileum to create a pouch on the inside of the abdominal wall to collect waste.
View recommendations for HTG503Show all sections
This document summarises the most common accessibility changes NICE is making in guidelines, and why
ProciseDx point-of-care platform for inflammatory bowel disease (MIB302)
NICE has developed a medtech innovation briefing (MIB) on ProciseDx point-of-care platform for inflammatory bowel disease .
In development Reference number: GID-TA11352 Expected publication date: TBC
Idelalisib for treating refractory follicular lymphoma (TA604)
Evidence-based recommendations on idelalisib (Zydelig) for follicular lymphoma that has not responded to 2 prior lines of treatment in adults.
Awaiting development Reference number: GID-TA11778 Expected publication date: TBC
methotrexate in the induction of remission in mild-to-moderate ulcerative colitis unresponsive to aminosalicylates? Any explanatory...
the induction of remission for people with mild-to-moderate ulcerative colitis? Any explanatory notes(if applicable) To find out why the...
ulcerative colitis? Any explanatory notes(if applicable) Source guidance details Comes from guidance Ulcerative colitis:...
ulcerative colitis? Any explanatory notes(if applicable) Source guidance details Comes from guidance Ulcerative colitis:...
placebo for induction of remission for people with subacute ulcerative colitis that is refractory to systemic corticosteroids? Any...
RIDASCREEN tests for monitoring infliximab in inflammatory bowel disease (MIB109)
NICE has developed a medtech innovation briefing (MIB) on RIDASCREEN tests for monitoring infliximab in inflammatory bowel disease .
Learn about NICE's proportionate approach to technology appraisals, which aims to streamline the evaluation process for new health technologies, ensuring timely access to innovative treatments while maintaining rigorous standards.